Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 7/20 | 0.51 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5891125 | 0.92 | AVPR2 (0.53) | AVPR2AVPR1ANAMPTNPC1SLC6A7 | |
| SCHEMBL5891130 | 0.92 | NAMPT (0.42) | AVPR2AVPR1ANAMPTALDH1A1NPC1 | |
| SCHEMBL5891185 | 0.90 | AVPR2 (0.50) | AVPR2AVPR1ANAMPTALDH1A1NPC1 | |
| SCHEMBL5891112 | 0.88 | AVPR2 (0.46) | AVPR2AVPR1ANAMPTALDH1A1NPC1 | |
| SCHEMBL5891396 | 0.85 | AVPR2 (0.51) | AVPR2AVPR1ASLC6A7 | |
| SCHEMBL5891642 | 0.85 | AVPR2 (0.46) | AVPR2AVPR1ANAMPTALDH1A1NPC1 | |
| SCHEMBL5891126 | 0.84 | AVPR2 (0.42) | AVPR2AVPR1ANAMPTALDH1A1NPC1 | |
| SCHEMBL5890748 | 0.83 | AVPR2 (0.49) | AVPR2AVPR1ANAMPTALDH1A1NPC1 | |
| SCHEMBL5891011 | 0.83 | AVPR2 (0.54) | AVPR2AVPR1ANAMPT | |
| SCHEMBL5784370 | 0.83 | AVPR2 (0.54) | AVPR2AVPR1ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064120-B2 | Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2006-06-20 | — | — | US | claimed |
| WO-2002083683-A9 | NOVEL TRICYCLIC PYRIDYL BENZAZEPINE CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH CORP (US) | 2004-02-26 | — | — | WO | claimed |
| US-20030055047-A1 | Novel tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH | 2003-03-20 | — | — | US | claimed |
| US-7064120-B2 | Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2006-06-20 | — | — | US | disclosed |
| US-20030055047-A1 | Novel tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055047-A1 | Novel tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | OXTR, OPRL1, OPRK1 | AVPR2 70/4885AVPR1A 33/4885NAMPT 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.